Natixis Advisors’s BridgeBio Pharma BBIO Stock Holding History

Natixis Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.94M	Buy	39,454 +18,384	+87%	+$1.29M	﹤0.01%	1098
2026 Q1	$1.56M	Buy	+21,070	New	+$1.53M	﹤0.01%	1203
2025 Q4	–	Sell	-18,948	Closed	-$984K	–	1605
2025 Q3	$984K	Buy	18,948 +5,015	+36%	+$245K	﹤0.01%	1322
2025 Q2	$602K	Buy	+13,933	New	+$507K	﹤0.01%	1430

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Natixis Advisors's BBIO Position: Q2 2026 in Review

Natixis Advisors increased its BridgeBio Pharma (BBIO) stake by 87% in Q2 2026, buying an estimated $1.29M and bringing the position to 39,454 shares worth $2.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1098.

Natixis Advisors first reported a position in BBIO in Q2 2025 and has held it in 4 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Natixis Advisors held 39,454 shares of BridgeBio Pharma worth $2.94M as of Q2 2026.
Natixis Advisors bought 18,384 BridgeBio Pharma shares in Q2 2026, an estimated $1.29M.
BridgeBio Pharma made up ﹤0.01% of Natixis Advisors's portfolio in Q2 2026, its #1098 holding.
Natixis Advisors first reported a position in BridgeBio Pharma in Q2 2025 and has held it in 4 quarters since.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.